Huizing Mt

Antwerp University Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Sevilay Altıntaş

Antwerp University Hospital

VAN OFFEL J

JB Vermorken

Antwerp University Hospital

Tjalma Wa

Antwerp University Hospital

Koolen Mg

Beijnen Jh

Utrecht University

Van Dam Pa

Antwerp University Hospital

Eric Van Marck

University of Antwerp

Jan Van den Brande

Antwerp University Hospital

N ODEUR

Cooperative Institutions

Antwerp University Hospital

University of Antwerp

The Netherlands Cancer Institute

Vrije Universiteit Amsterdam

Utrecht University

Oncode Institute

Erasmus MC

University Medical Center Utrecht

University of Amsterdam

Academic Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Small-cell carcinoma of the penile urethra: a case report and a short review of the literature

Annals of Oncology (2006)

Sevilay Altıntaş N. Blockx Huizing Mt Jan Van den Brande Lucien Hoekx

The diffuse neuroendocrine-cell system (DNS) consists of a wide variety of cells that are present in the central and peripheral nervous system and in many classic endocrine organs. These cells share the ability to produce many biologically active amines, peptides and other substances (such as neuron-specific enolase, chromogranines, synaptophysin and Leu-7). Cells and neoplasms of the DNS are divided into two groups: those of the neural type and those of the epithelial type which includes neuroendocrine tumors (NETs) from numerous sites.

Synaptophysin

Enolase

Cell type

Enteroendocrine cell

10.1093/annonc/mdl457

Cite

Citations (19)

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives.

PubMed (2015)

K Papadmitriou Trinh Xb Sevilay Altıntaş Van Dam Pa Huizing Mt

Trastuzumab was the first targeted therapy for HER2 positive breast cancer. It has become the standard of care for HER2 positive metastatic breast cancer since 2000 and in the adjuvant setting since 2006. Adjuvant it is given for a year and in patients with metastatic disease until progression. The standard mode of administration is intravenous. Recently a subcutaneous form has become available. A phase III study showed that there is no difference between the intravenous and subcutaneous form in terms of safety and efficacy. The patient's preference however significantly favoured the subcutaneous form. It is estimated that the use of the SC form could contribute to a cost saving between 758 and 2576 euro per annual course. For Belgium alone this could mean an estimated saving of 1.4 to 4.6 million euros per year. The potential benefit of the SC administration for healthcare facilities could be further increased when applied in a LEAN working day-care chemotherapy unit. After reviewing the existing literature we suggest to further validate the potential financial impact of SC trastuzumab compared to the traditional IV form and to introduce a scientific proposal incorporating the benefits of this formulation in a LEAN working healthcare unit.

Subcutaneous injection

Euros

Route of administration

Source

Cite

Citations (18)

Clinical pharmacology of carboplatin administered in combination with paclitaxel.

PubMed (1997)

van Warmerdam Lj Huizing Mt Giuseppe Giaccone Postmus Pe ten Bokkel Huinink Ww

Carboplatin

Source

Cite